Entrada Therapeutics, Inc.
TRDA
$8.17
-$0.16-1.92%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 63.38% | 146.92% | 451.22% | 544.79% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.38% | 146.92% | 451.22% | 544.79% | -- |
| Cost of Revenue | 25.45% | 37.71% | 32.22% | 42.43% | 49.96% |
| Gross Profit | 193.44% | 84,207.08% | 415.82% | 217.95% | 143.73% |
| SG&A Expenses | 19.12% | 11.11% | 5.58% | 5.00% | 5.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.90% | 30.33% | 24.71% | 31.10% | 35.92% |
| Operating Income | 1,586.75% | 271.74% | 226.98% | 129.34% | 96.75% |
| Income Before Tax | 451.47% | 451.04% | 269.89% | 153.25% | 112.74% |
| Income Tax Expenses | -95.42% | -- | -65.90% | 379.33% | -- |
| Earnings from Continuing Operations | 1,081.69% | 352.42% | 226.80% | 129.50% | 92.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,081.69% | 352.42% | 226.80% | 129.50% | 92.93% |
| EBIT | 1,586.75% | 271.74% | 226.98% | 129.34% | 96.75% |
| EBITDA | 15,920.56% | 297.65% | 235.89% | 134.21% | 99.66% |
| EPS Basic | 1,056.21% | 337.25% | 219.96% | 127.57% | 93.10% |
| Normalized Basic EPS | 469.80% | 431.31% | 259.31% | 149.88% | 111.83% |
| EPS Diluted | 837.20% | 310.46% | 214.86% | 124.89% | 91.47% |
| Normalized Diluted EPS | 482.58% | 408.10% | 253.72% | 147.75% | 111.05% |
| Average Basic Shares Outstanding | 12.83% | 8.84% | 4.79% | 5.55% | 5.60% |
| Average Diluted Shares Outstanding | 15.18% | 9.59% | 8.00% | 7.76% | 6.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |